OneMedPlace - Sentinel

OneMedForumNY 2013, June 26-27

OneMedPlace Team — Fri, 17 May 2013 19:36:08 +0000

NEW YORK, October 3, 2012 – OneMedPlace has announced programming themes for its 6th Annual OneMedForum, taking place January 7-9th, 2013, at the Sir Francis Drake Hotel in San Francisco.

PDUFA: Flamel Technologies S.A. — Undisclosed Product, May 31, 2013

Herina Ayot — Fri, 17 May 2013 19:35:19 +0000

PUDFA: DepoMed, Inc. — Serada, May 31, 2013

MMargolis — Fri, 17 May 2013 17:42:16 +0000

Earnings: Athersys Inc. — May 16, 2013

MMargolis — Fri, 17 May 2013 17:39:20 +0000

MAPPING THE “B.R.A.I.N.”

OneMedPlace Team — Fri, 17 May 2013 13:00:31 +0000

On April 2nd, 2013, U.S. President Barack Obama unveiled the “BRAIN” Initiative, which is short for Brain Research through Advancing Innovative Neurotechnologies. The BRAIN Initiative may be known as the spiritual successor to the Human Genome Project, not only for its desire to understand a mysterious place known to medical science, but for taking its cues from the initial success of the HGP.

Bioinformatics Special Report, Part I: Where Does Biotechnology Data Come From?

OneMedPlace Team — Thu, 16 May 2013 20:15:50 +0000

Bioinformatics is the field of science involved with using computational methods to convert raw biological data into meaningful biological paradigms. Part I of this article will discuss how bioinformatics data is generated. It will focus on the methods used to collect this data, and the companies that support this collection.

Editor’s Note: May 2, 2013

Herina Ayot — Thu, 02 May 2013 17:06:19 +0000

Hard to believe we are just a few weeks away from OneMedForumNY 2013, June 26-27 in New York City. We’re excited to host a group of very promising companies with unique technology, and expect over 500 attendees.

Our Sentinel this week features radio interviews with two executives of companies operating in regenerative medicine and medical marijuana. Both companies have products on the market, and both are about to take advantage of some significant sector growth.

In addition, we profile two newly public companies with demonstrated clinical success, and point

ISTO Technologies CFO: No Other Company Can Grow Living Cartilage in a Lab Setting

OneMedPlace Team — Tue, 30 Apr 2013 16:35:19 +0000

ISTO Technologies has a unique pipeline that has demonstrated both clinical progress and market success. With one commercialized product -- a bone graft extender and substitute -- and two late-stage clinical programs focusing in engineering cartilage tissue for knee and back, respectively, the company is poised to capture an opportunistic yet untapped market. OneMedRadio spoke with CFO Scott Gill about market opportunity, and finding success in a notoriously unfriendly space.

Release: Actium Biosystems Appoints Distinguished Pharmaceutical Scientist Dr. Jessie L.-S. Au to its Scientific Advisory Board

OneMedPlace Team — Mon, 29 Apr 2013 19:18:39 +0000

Actium Cancer Treatment (ACT) platform’s controlled heat (hyperthermia) has the potential to substantially increase the efficacy of chemotherapy and radiation First application: non-muscle-invasive bladder cancer (NMIBC).

Atossa Genetics’ Portfolio Can Detect Breast Cancer. But Can These Products Eradicate It?

OneMedPlace Team — Mon, 29 Apr 2013 13:06:31 +0000

Atossa Genetics believes it can prevent breast cancer by 2020 -- and in the meantime, capture a unique market opportunity -- with their novel cellular and molecular diagnostic risk assessment products for early detection. Yet in a burgeoning diagnostics space, and rapid advancement in cancer therapeutics, will this company find a niche?

DelMar IPO Obscurity Could Offer Investors Favorable Entry

OneMedPlace Contributor — Fri, 26 Apr 2013 13:06:31 +0000

DelMar Pharmaceuticals (DMPI.OB) started 2013 with a revealing corporate update on January 8th. In the update, president and CEO Jeffrey Bacha outlined his goals with an exciting year ahead for the company and its employees. Mr. Bacha focused primarily on the company's lead product candidate, VAL-083, a small molecule (chemotherapy) agent that DelMar is developing in a dose escalation trial for recurrent glioblastoma multiforme (GBM).

Release: Idrasil, Cannabis in a Pill Founder to Exhibit at the Rx for Wealth Symposium April 27 in Huntington Beach

OneMedPlace Team — Thu, 25 Apr 2013 16:38:49 +0000

Huntington Beach, April 23, 2013 – Steele C. Smith, III and Medical Director Mark S. Wagner M.D. to exhibit at the Rx for Wealth Network Symposium this Weekend April 27th at the Huntington Beach Hilton.

White Paper Explores the Amarantus Bioscience Alzheimer’s Disease Diagnostic

OneMedPlace Team — Thu, 25 Apr 2013 13:53:11 +0000

Amarantus Bioscience has posted a White Paper exploring the company's LymPro Alzheimer's Disease diagnostic, prepared by a member of the company's Board of Advisors. The Paper discusses the increasing prevalence of Alzheimer’s disease, the clinical and economic advantages of early detection, and why the LymPro Test is poised to potentially become the market leading diagnostic product in the Alzheimer’s space.

Idrasil: The First Medical Marijuana Pill, and Parallels in Opiate Market

OneMedPlace Team — Wed, 24 Apr 2013 21:39:57 +0000

California-based C3 International has brought to market the first medical marijuana pill, known as Idrasil. OneMedRadio spoke with C3 International Chairman Steele Clarke Smith III about the unique delivery technology behind Idrasil, and trends in the sector related to market opportunity, necessity for non-inhaled delivery and dialogue in the medical community.

The Beginning of a Shift at Tekmira: From Focus on Delivery to Therapy

Jake King — Tue, 23 Apr 2013 15:25:56 +0000

Tekmira’s (TKMR) story over the last few years has largely been focused on its siRNA delivery technology, lipid nanoparticles (LNPs), and the ability of the platform to be used in broader RNAi applications. But the focus of investors is shifting as Tekmira brings a new therapy into the clinic this year and moves out of early-stage clinical development and into proof-of-concept studies.